The Alliance for Regenerative Medicine Announces 2017 Cell & Gene Therapies State of the Industry Briefing

– December 14, 2016

WASHINGTON, D.C., December 15, 2016 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapies and broader regenerative medicine sector, announced its 2017 Cell & Gene Therapies State of the Industry briefing will take place January 9, 2017 in San Francisco, held in conjunction with Biotech Showcase™ 2017.

ARM’s State of the Industry briefing is the largest cell and gene therapy-focused annual event taking place during JP Morgan week, and is expected to attract more than 400 of the field’s leading executives, investors, patient advocates and academic leaders.

“This past year we saw continued clinical progress with multiple therapeutic approaches addressing a broad range of urgent unmet medical needs ranging from potential cures for rare genetic disorders to complete remission for certain forms of cancer,” said Morrie Ruffin, ARM’s managing director. “2017 holds significant promise as we move towards commercialization with many promising gene and cell therapies and other regenerative medicine programs.”

Offering a comprehensive industry overview, this briefing offers insights into key sector trends and metrics, the financial and partnering outlook, and a discussion of anticipated clinical data events, recent advances, commercialization challenges and a preview of the coming year.

Program Agenda:
8:00 – 8:20am | Introduction & Industry Update
Robert Preti, Chairman, Alliance for Regenerative Medicine; President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences

8:20 – 9:05am | Cell Therapies: Essential Requirements for Near-Term and Long-Term Commercial Success
Thomas Farrell, President and CEO, Bellicum Pharmaceuticals
Manfred Rüdiger, CEO, Kiadis Pharma
Jeff Walsh, Chief Financial and Strategy Officer, bluebird bio

9:05 – 9:50am | The Gene Therapy Pipeline: Will Clinical and Regulatory Progress Match Patient and Investor Expectations?
Nessan Bermingham, CEO, President and Founder, Intellia Therapeutics
Barrie Carter, VP Vector Biology, BioMarin Pharmaceutical

Registration is free and open to the public; however, an RSVP is required.

The briefing will take place at the Parc 55 Hilton, 55 Cyril Magnin Street in San Francisco, California from 8:00 to 10:00am and is held in conjunction with Biotech Showcase™, organized by EBD Group and Demy Colton. Please note that attendance at this briefing is separate from registering to attend the Biotech Showcase™ conference, which requires paid registration. For full details on Biotech Showcase™, please visit the website.

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 250 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit